Previous 10 | Next 10 |
Evolus (EOLS): Q4 GAAP EPS of -$3.28 misses by $2.94.Revenue of $20.58M (+5.8% Y/Y) beats by $0.28M.Cash, cash equivalents and short-term investments as of December 31, 2020 were $107.6 million.Pro forma cash position at December 31, 2020 was $57 million.Outlook: The company an...
Q4 2020 Net Revenue $20.6 Million, Highest Net Revenue Quarter Since Launch of Jeuveau ® Pro Forma Cash Position of $57 Million at December 31, 2020 1 NEWPORT BEACH, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance ...
Ahead of its financial results for Q4 2020 to be announced tomorrow, Evolus ([[EOLS]] +12.9%) disclosed several transactions with its strategic partner Daewoong Pharmaceutical aimed at improving the company’s financial position.With plans to focus on the growth of Jeuvea...
NEWPORT BEACH, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its fourth quarter and year end 2020 financial results a...
Pro Forma Cash Position of $57 Million at December 31, 2020 1 NEWPORT BEACH, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced s...
This continues our series on busting options myths where we explore a different way to sell options. In this article, we discuss myths around selling puts. These myths generally teach: (i) only sell puts on companies you wouldn't mind owning; (ii) selling puts requires a neutral t...
Gainers: [[RUBY]] +16.8%. [[SALM]] +7.5%. [[NXPI]] +5%. [[CHMA]] +3.5%. [[UBX]] +2.7%.Losers: [[CLPS]] -4.2%. [[AMTX]] -3.9%. [[VRAY]] -3.2%. [[TPIC]] -2.8%. [[EOLS]] -2.5%. For further details see: NXPI, TPIC, EOLS and UBX among after-hours movers
Gainers: [[SNSE]] +17.5%. [[ABCL]] +8.3%. [[AGLE]] +7.6%. [[OLED]] +5.9%. [[EOLS]] +5.4%.Losers: [[CRWD]] -7.0%. [[ARDX]] -6.9%. [[NK]] -6.6%. [[CATB]] -3.2%. [[ISEE]] -3.1%. For further details see: SNSE, AGLE, CRWD and ISEE among after-hours movers
NEWPORT BEACH, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the promotion of Crystal Muilenburg from VP, Corporate Communications & PR to ...
Truist analyst Gregg Gilbert has cut shares of Evolus, Inc. (EOLS) from buy to hold.He writes that with the Evolus' recent IP settlement with Abbvie (ABBV) and Medytox over Jeuveau, the company's stock is readjusting to a more fair value.However, he says he is still "bullish on managemen...
News, Short Squeeze, Breakout and More Instantly...
Total Net Revenue of $66.9 Million for Q2 2024, Up 36% from Q2 2023 Raises Full-Year 2024 Net Revenue Guidance to $260 Million to $270 Million, Representing Year-Over-Year Growth of 34% at the Top End Improved Quarterly GAAP Operating Loss to $7.7 Million; Delivered First Ever Qua...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will host an Investor Day on Thursday, September 12, 2024 in New York City. Attendees can join in-person or participate via webcast. The even...
Launching into this growth market 1 as part of the company’s geographic expansion strategy Evolus Australia established to drive medical education, training, marketing and sales to medical aesthetics healthcare professionals Evolus, Inc. (NASDAQ: EOLS), a perf...